Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients With Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

NCT04883437 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04883437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04883437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients With Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
September 3, 2021
Completion date
January 15, 2027
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, indolent non-hodgkin lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative disorder, mantle cell lymphoma, marginal zone lymphoma